Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias - PubMed (original) (raw)
. 2007 Mar 15;22(4):533-9.
doi: 10.1002/mds.21308.
Affiliations
- PMID: 17230470
- DOI: 10.1002/mds.21308
Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias
Vincent Paillé et al. Mov Disord. 2007.
Abstract
Parkinson's disease (PD) is characterized by the bilateral degeneration of the midbrain dopamine-containing neurons with the most severe lesion in the posterolateral part of the substantia nigra pars compacta (SNpc). In humans, such lesions lead to specific motor abnormalities (i.e., akinesia, rigidity, and tremor) that are greatly improved by levodopa treatment. After a few years, the beneficial effect of the treatment is frequently offset by the development of dyskinesias. To improve treatment strategies, an animal model showing most of the histological and clinical characteristics of the human disease is mandatory. Ten rats received a bilateral injection of small doses of 6-OHDA in the medial forebrain bundle (MFB) and were compared with five sham-lesioned rats. The 6-OHDA-lesioned rats progressively developed abnormal motor behavior (assessed by the stepping test) compared with the sham-lesioned rats. The lesioned rats greatly improved under levodopa treatment, but developed concomitant dyskinesias. All 6-OHDA-lesioned animals had bilateral partial lesions of the SNpc, with the most severe lesion being in its posterolateral part. There was a significant correlation between the severity of the dopaminergic cell loss and the severity of the levodopa-induced dyskinesias. These rats constitute an interesting model of PD, sharing some of the main characteristics of the human disease.
(c) 2006 Movement Disorder Society.
Similar articles
- Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK, Shukla S, Seth K, Chauhan S, Sinha C, Shukla Y, Agrawal AK. Chaturvedi RK, et al. Neurobiol Dis. 2006 May;22(2):421-34. doi: 10.1016/j.nbd.2005.12.008. Epub 2006 Feb 9. Neurobiol Dis. 2006. PMID: 16480889 - Subthalamic 6-OHDA-induced lesion attenuates levodopa-induced dyskinesias in the rat model of Parkinson's disease.
Marin C, Bonastre M, Mengod G, Cortés R, Rodríguez-Oroz MC, Obeso JA. Marin C, et al. Exp Neurol. 2013 Dec;250:304-12. doi: 10.1016/j.expneurol.2013.10.006. Epub 2013 Oct 18. Exp Neurol. 2013. PMID: 24140562 - Electrophysiological characterization of substantia nigra dopaminergic neurons in partially lesioned rats: effects of subthalamotomy and levodopa treatment.
Bilbao G, Ruiz-Ortega JA, Miguens N, Ulibarri I, Linazasoro G, Gómez-Urquijo S, Garibi J, Ugedo L. Bilbao G, et al. Brain Res. 2006 Apr 21;1084(1):175-84. doi: 10.1016/j.brainres.2006.02.052. Epub 2006 Mar 30. Brain Res. 2006. PMID: 16574080 - [Motor symptoms in Parkinson disease].
Larsen JP, Beiske AG, Bekkelund SI, Dietrichs E, Tysnes OB, Vilming ST, Aasly JO. Larsen JP, et al. Tidsskr Nor Laegeforen. 2008 Sep 25;128(18):2068-71. Tidsskr Nor Laegeforen. 2008. PMID: 18846123 Review. Norwegian. - Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
Olanow CW. Olanow CW. Mov Disord. 2008;23 Suppl 3:S613-22. doi: 10.1002/mds.22061. Mov Disord. 2008. PMID: 18781663 Review.
Cited by
- Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease.
Bagetta V, Sgobio C, Pendolino V, Del Papa G, Tozzi A, Ghiglieri V, Giampà C, Zianni E, Gardoni F, Calabresi P, Picconi B. Bagetta V, et al. J Neurosci. 2012 Dec 5;32(49):17921-31. doi: 10.1523/JNEUROSCI.2664-12.2012. J Neurosci. 2012. PMID: 23223310 Free PMC article. - Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors.
Paquette MA, Martinez AA, Macheda T, Meshul CK, Johnson SW, Berger SP, Giuffrida A. Paquette MA, et al. Eur J Neurosci. 2012 Nov;36(9):3224-34. doi: 10.1111/j.1460-9568.2012.08243.x. Epub 2012 Aug 3. Eur J Neurosci. 2012. PMID: 22861201 Free PMC article. - Dopamine dysregulation in a mouse model of paroxysmal nonkinesigenic dyskinesia.
Lee HY, Nakayama J, Xu Y, Fan X, Karouani M, Shen Y, Pothos EN, Hess EJ, Fu YH, Edwards RH, Ptácek LJ. Lee HY, et al. J Clin Invest. 2012 Feb;122(2):507-18. doi: 10.1172/JCI58470. Epub 2012 Jan 3. J Clin Invest. 2012. PMID: 22214848 Free PMC article. - Motor disturbances and thalamic electrical power of frequency bands' improve by grape seed extract in animal model of Parkinson's disease.
Sarkaki A, Eidypour Z, Motamedi F, Keramati K, Farbood Y. Sarkaki A, et al. Avicenna J Phytomed. 2012 Fall;2(4):222-32. Avicenna J Phytomed. 2012. PMID: 25050252 Free PMC article. - Levodopa-induced dyskinesia is associated with increased thyrotropin releasing hormone in the dorsal striatum of hemi-parkinsonian rats.
Cantuti-Castelvetri I, Hernandez LF, Keller-McGandy CE, Kett LR, Landy A, Hollingsworth ZR, Saka E, Crittenden JR, Nillni EA, Young AB, Standaert DG, Graybiel AM. Cantuti-Castelvetri I, et al. PLoS One. 2010 Nov 10;5(11):e13861. doi: 10.1371/journal.pone.0013861. PLoS One. 2010. PMID: 21085660 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous